AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8789313 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 98
Study 2305417 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐disopyramide
Number of subjects: 6
Study 2305417 — intervention group
Group type: COMPARATOR
Intervention: R(‐)‐disopyramide
Number of subjects: 6
Study 6773161 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium
Number of subjects: 9
Study 6773161 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 9
Study 30776898 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CPR (resuscitation-retraining programme)
Number of subjects: 79
Study 30776898 — intervention group
Group type: COMPARATOR
Intervention: G-Stan (standard programme)
Number of subjects: 79
Study 26946616 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbs for tonifying Qi and kidney, and replenishing spleen
Number of subjects: 60
Study 26946616 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 60
Study 24784832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) snack (0.4 g carbohydrate/kg body mass)
Number of subjects: 10
Study 24784832 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) snack (0.4 g carbohydrate/kg body mass)
Number of subjects: 10
Study 24784832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meal types (LGI and HGI)
Number of subjects: 10
Study 22472562 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 69
Study 20823895 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol monthly (1600 U/day)
Number of subjects: 210
Study 20823895 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol bimonthly (800 U/day)
Number of subjects: 210
Study 20823895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 17427923 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying an infant in one's arms
Number of subjects: 0
Study 17427923 — intervention group
Group type: COMPARATOR
Intervention: Using a tool to sling the infant
Number of subjects: 0
Study 17427923 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a baby in one's arms
Number of subjects: 0
Study 17427923 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider bi-trochanteric width
Number of subjects: 0
Study 15834750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitek 2 system (bioMerieux, Marcy l'Etoile, France)
Number of subjects: 0
Study 15834750 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (overnight methods for identification and susceptibility testing)
Number of subjects: 0
Study 12495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training twice per week (n = 20)
Number of subjects: 55
Study 12495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training once per week (n = 22)
Number of subjects: 55
Study 12495243 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 55
Study 9523803 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine (45 mg)
Number of subjects: 60
Study 9523803 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (60 mg)
Number of subjects: 60
Study 7892823 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 7892823 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1829
Study 2692654 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cyclophosphamide
Number of subjects: 2230
Study 2692654 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen
Number of subjects: 2230
Study 2692654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide and tamoxifen
Number of subjects: 2230
Study 202425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium oxide
Number of subjects: 52
Study 202425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30816107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with developing line
Number of subjects: 77
Study 30816107 — intervention group
Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 77
Study 30338528 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally provocative clip
Number of subjects: 158
Study 30338528 — intervention group
Group type: COMPARATOR
Intervention: Emotionally neutral clip
Number of subjects: 158
Study 30338528 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally provocative clip (remotely)
Number of subjects: 158
Study 30338528 — intervention group
Group type: COMPARATOR
Intervention: Emotionally neutral clip (remotely)
Number of subjects: 158
Study 26369888 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tidal volume (20 ml kg(‐1) ideal body weight)
Number of subjects: 33
Study 26369888 — intervention group
Group type: COMPARATOR
Intervention: Standard tidal volume (10 ml kg(‐1) ideal body weight)
Number of subjects: 33
Study 25179854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral exercise intervention (GMCB)
Number of subjects: 80
Study 25179854 — intervention group
Group type: COMPARATOR
Intervention: Traditional center-based exercise therapy (TRAD)
Number of subjects: 80
Study 25179854 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCB
Number of subjects: 80
Study 25179854 — intervention group
Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 80
Study 22877317 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mechanical Post-Conditioning (MMPOC)
Number of subjects: 79
Study 22877317 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 20820932 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD-UFA (47 g SFA/d)
Number of subjects: 8
Study 20820932 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD-SFA (86 g/d SFA)
Number of subjects: 8
Study 20820932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CRD
Number of subjects: 8
Study 20820932 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD-SFA
Number of subjects: 8
Study 20820932 — intervention group
Group type: EXPERIMENTAL
Intervention: CRD-UFA
Number of subjects: 8
Study 17001492 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based walking intervention
Number of subjects: 36
Study 17001492 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-list)
Number of subjects: 36
Study 16999714 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (GH) and chondroitin sulfate (CS)
Number of subjects: 0
Study 16999714 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate (GS), glucosamine hydrochloride (GH), and chondroitin sulfate (CS)
Number of subjects: 0
Study 12589390 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 13
Study 12589390 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 13
Study 12589390 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 13
Study 12589390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10224952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Obsessional Compulsive Inventory (MOCI)
Number of subjects: 0
Study 10224952 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCI
Number of subjects: 0
Study 8546475 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (40 micrograms/kg)
Number of subjects: 95
Study 8546475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of granisetron and methylprednisolone (MP: 10 mg/kg)
Number of subjects: 95
Study 2070983 — intervention group
Group type: EXPERIMENTAL
Intervention: New low-sodium cleansing solution
Number of subjects: 78
Study 2070983 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene glycol solution
Number of subjects: 78
Study 2070983 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both solutions
Number of subjects: 78
Study 2070983 — intervention group
Group type: EXPERIMENTAL
Intervention: Saltiness perception
Number of subjects: 78
Study 6403021 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 20
Study 6403021 — intervention group
Group type: COMPARATOR
Intervention: prajmalium bitartrate
Number of subjects: 20
Study 31077127 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) without surgery (Group 1)
Number of subjects: 18
Study 31077127 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) + abdominoperineal resection (APR) (Group 2)
Number of subjects: 18
Study 28530840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneously every 4 weeks or every 8 weeks)
Number of subjects: 369
Study 28530840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 28530840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (every 4 weeks)
Number of subjects: 369
Study 28530840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (every 8 weeks)
Number of subjects: 369
Study 28530840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (both regimens)
Number of subjects: 369
Study 25748471 — intervention group
Group type: EXPERIMENTAL
Intervention: DB-ACLR using footprint remnant procedure (EF group)
Number of subjects: 72
Study 25748471 — intervention group
Group type: COMPARATOR
Intervention: DB-ACLR using bony landmark procedure (BL group)
Number of subjects: 72
Study 23432408 — intervention group
Group type: EXPERIMENTAL
Intervention: L. casei strain Shirota fermented milk
Number of subjects: 90
Study 23432408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21352464 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 77
Study 21352464 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 77
Study 21352464 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 77
Study 21352464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21352464 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 77
Study 19525832 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (group A, n = 32)
Number of subjects: 65
Study 19525832 — intervention group
Group type: COMPARATOR
Intervention: Titanium mesh cages (group B, n = 33)
Number of subjects: 65
Study 17727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Talnetant 25 mg
Number of subjects: 102
Study 17727393 — intervention group
Group type: EXPERIMENTAL
Intervention: Talnetant 100 mg
Number of subjects: 102
Study 17727393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 15453971 — intervention group
Group type: EXPERIMENTAL
Intervention: Elicitation tasks and auditory priming study
Number of subjects: 4
Study 12408444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG
Number of subjects: 45
Study 12408444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9680900 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (0.05%)‐sodium fluoride (0.04%)‐strontium (100 ppm as SrCl2) rinsing solution (CXFSr)
Number of subjects: 18
Study 9680900 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study 7844233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (150 mg or 300 mg daily) starting from day 13 of HRT
Number of subjects: 99
Study 7844233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin starting from day 1 of HRT
Number of subjects: 99
Study 7844233 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 99
Study 2810695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 12000 U.kg‐1
Number of subjects: 0
Study 2810695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 6000 U.kg‐1
Number of subjects: 0
Study 2810695 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1097194 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg indapamide daily
Number of subjects: 38
Study 1097194 — intervention group
Group type: COMPARATOR
Intervention: 100 mg chlorthalidone daily
Number of subjects: 38
Study 30317902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation
Number of subjects: 0
Study 30317902 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation
Number of subjects: 0
Study 30691768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 44
Study 30691768 — intervention group
Group type: COMPARATOR
Intervention: Friction massage
Number of subjects: 44
Study 28697102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g secnidazole
Number of subjects: 215
Study 28697102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g secnidazole
Number of subjects: 215
Study 28697102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 25858178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring in CBT (12-16 sessions)
Number of subjects: 201
Study 25858178 — intervention group
Group type: COMPARATOR
Intervention: Brief treatment programme (3 sessions of breathing retraining and education)
Number of subjects: 201
Study 23686891 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 1.5 ng/mL (R1.5)
Number of subjects: 105
Study 23686891 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 2 ng/mL (R2)
Number of subjects: 105
Study 23686891 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at effect-site concentration of 1 ng/mL (R1)
Number of subjects: 105
Study 21401801 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (3‐monthly spirometry with medical review)
Number of subjects: 195
Study 21401801 — intervention group
Group type: COMPARATOR
Intervention: Group B (spirometry only before and after the trial)
Number of subjects: 195
Study 21401801 — intervention group
Group type: COMPARATOR
Intervention: Group C (usual care)
Number of subjects: 195
Study 21401801 — intervention group
Group type: COMPARATOR
Intervention: Group A vs Groups B + C
Number of subjects: 195
Study 19824278 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TF)
Number of subjects: 5
Study 19824278 — intervention group
Group type: COMPARATOR
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 5
Study 18060626 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + atorvastatin (10 mg/day)
Number of subjects: 48
Study 18060626 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 48
Study 15544079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding screw device combined with calcium‐phosphate cement for augmentation
Number of subjects: 21
Study 15544079 — intervention group
Group type: COMPARATOR
Intervention: Sliding screw device alone (Controls)
Number of subjects: 21
Study 11227321 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic oriented psychotherapy in addition to standardized medical treatment
Number of subjects: 108
Study 11227321 — intervention group
Group type: COMPARATOR
Intervention: Standardized medical treatment (Control group)
Number of subjects: 108
Study 11227321 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic oriented psychotherapy
Number of subjects: 108
Study 9662680 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 14
Study 9662680 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise/Study
Number of subjects: 14
Study 9662680 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 9662680 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Only
Number of subjects: 14
Study 7920211 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day) and vitamin A (25,000 international units/day)
Number of subjects: 2319
Study 7920211 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 2319
Study 2112188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 432
Study 2112188 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (IMV)
Number of subjects: 432
Study 7537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 134
Study 7537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 134
Study 7537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 31150601 — intervention group
Group type: COMPARATOR
Intervention: US-guided standard subacromial injection
Number of subjects: 60
Study 31150601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target injection (subacromial bursa plus proximal biceps long-head tendon)
Number of subjects: 60
Study 28439629 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 70
Study 28439629 — intervention group
Group type: COMPARATOR
Intervention: Lateral Approach (LA)
Number of subjects: 70
Study 24919604 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fibre (15 g day⁻¹)
Number of subjects: 10
Study 24919604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (15 g day⁻¹)
Number of subjects: 10
Study 24919604 — intervention group
Group type: COMPARATOR
Intervention: Control (refined grain, 15 g day⁻¹)
Number of subjects: 10
Study 23212552 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-2.5-percutaneous left-ventricular assist device
Number of subjects: 120
Study 20950324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating frequency (AE) stimulation
Number of subjects: 27
Study 20950324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LE) stimulation
Number of subjects: 27
Study 20950324 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (SE)
Number of subjects: 27
Study 19634943 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed extinction (extinction training 1 day later)
Number of subjects: 0
Study 19634943 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate extinction (extinction training 5 min later)
Number of subjects: 0
Study 17531699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 multifocal IOL
Number of subjects: 50
Study 17531699 — intervention group
Group type: COMPARATOR
Intervention: Array SA40 multifocal IOL
Number of subjects: 50
Study 15362934 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily of 95% ethyl esters of eicosapentaenoic acid (EPA)
Number of subjects: 28
Study 15362934 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (OA)
Number of subjects: 28
Study 15362934 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 28
Study 15362934 — intervention group
Group type: COMPARATOR
Intervention: OA
Number of subjects: 28
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 12
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 12
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 12
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 12
Study 10631623 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Paroxetine (comparison)
Number of subjects: 12
Study 10631623 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Venlafaxine (comparison)
Number of subjects: 12
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12
Study 10631623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 12
Study 10631623 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Venlafaxine
Number of subjects: 12
Study 8725855 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol . kg-1 . min-1)
Number of subjects: 11
Study 8725855 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study 1305301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraconservative, sealed composite resin restorations
Number of subjects: 0
Study 1305301 — intervention group
Group type: COMPARATOR
Intervention: Ultraconservative, localized, sealed amalgam restorations
Number of subjects: 0
Study 1305301 — intervention group
Group type: COMPARATOR
Intervention: Traditional, unsealed amalgam restorations
Number of subjects: 0
Study 3881104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 15
Study 3881104 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 15
Study 3881104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day and Propranolol 240 mg/day combined
Number of subjects: 15
Study 3881104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31651321 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention comprising education about dementia, counselling and group sessions
Number of subjects: 208
Study 31651321 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 208
Study 29985236 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Administration Threshold (CAT+), defined as 3 U or greater RBC in the first hour
Number of subjects: 680
Study 29985236 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation Intensity (RI4+), defined as 4 U or greater total products in the first 30 minutes
Number of subjects: 680
Study 29985236 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation Intensity (RI) as a continuous variable
Number of subjects: 680
Study 29985236 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CAT+ and RI4+
Number of subjects: 680
Study 24915543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (2.4 g/day)
Number of subjects: 14
Study 24915543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil (16.2 g/day)
Number of subjects: 14